ArticleCureus2026
LigaSure™ Hemorrhoidectomy for Complex Grade III Hemorrhoidal Disease: A Prospective, Single-Center, Cohort Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGrade III hemorrhoidal disease (HD) with large-volume or circumferential prolapse is poorly managed with less invasive treatments. This study evaluates LigaSure™ (Covidien plc, Dublin, Ireland; now acquired by Medtronic plc, Galway, Ireland) hemorrhoidectomy outcomes in this subset.
methodsThis was a prospective single-center cohort study conducted in Najaf Province, Iraq, which enrolled 316 adults with Grade III HD and at least one "special" feature (large solitary prolapse ≥3 cm or ≥1 quadrant, circumferential prolapse ≥3 quadrants, perianal fibrosis/edema, or prior failed rubber band ligation (RBL)/dearterialization (DEART)/stapled hemorrhoidopexy (SH)), from February 2023 to October 2024, with a follow-up to October 2025. Primary endpoints included operative time and 30-day complications (visual analog scale ≥7 pain, urinary retention, bleeding, infection, stenosis, incontinence). Secondary outcomes included length of stay (LOS), recovery time, and one-year recurrence.
resultsMedian age of participants was 30 years (range 18-55). Of the total participants, 62.7% were male, and 48.1% had prior failed therapy. Mean operative time was 28.0 ± 6.0 minutes. Severe pain was recorded in 6.9% (95% CI 4.4-10.3), urinary retention in 17.1% (95% CI 13.1-21.7); the rate of postoperative urinary retention was higher with spinal (19.6%, n=240) versus general anesthesia (9.2%, n=76). The risk difference was 12.5% (95% CI 3.2-21.8). No bleeding, infection, stenosis, or incontinence was seen. Median LOS was one day (IQR 1, 1), and median recovery duration was seven days (IQR 6, 9). The one-year follow-up rate was achieved in 91.5% (289/316) of the patients. There were no patients with reoperation, and 11.8% had minor bleeding (95% CI 8.3-16.1). Outcomes were similar regardless of prior treatment failure.
conclusionStandardized LigaSure hemorrhoidectomy for complex Grade III HD demonstrated rapid operative times, low severe pain, acceptable urinary retention (higher with spinal anesthesia), and zero one-year reoperations, supporting early excisional surgery in this anatomical subset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.